AI-Enhanced Phage Therapy Emerges as Weapon Against Antibiotic-Resistant Superbugs

As antibiotic resistance escalates, a new strategy merges artificial intelligence with bacteriophage therapy to combat hard-to-treat infections. Traditional drug development struggles because antibiotics indiscriminately kill both harmful and beneficial microbes, whereas engineered phages can be programmed to target only pathogenic bacteria. Recent deep-learning advances dramatically improve predictions of phage-host interactions, allowing rapid identification of effective natural phages and the design of custom synthetic variants.

Structural modeling platforms like AlphaFold and OpenFold help visualize key phage proteins, guiding precise modifications to enhance bacterial binding and lysis. Nonetheless, bacteria can evolve resistance to single-phage attacks, necessitating multi-phage cocktails and careful timing. Moreover, most AI models operate in silico, and their real-world performance and interpretability remain under investigation before widespread clinical use.